Mats Blom is a Swedish business executive who has held various positions in the pharmaceutical and finance industries. Mats is currently a board member at Egetis Therapeutics.
Blom began their career as a senior manager at Ernst & Young Corporate Finance, where they worked from 2002 to 2004. Mats then became the CFO of Anoto Group AB, an international IT company listed on the Stockholm Stock Exchange, in 2005. Mats held this position until 2007, when they left to become the CFO of Swedish Orphan AB.
In 2010, Blom joined Zealand Pharma as their CFO. Mats remained in this position until 2019, when they left to join Hansa Biopharma AB (publ) as a board member.
Mats Blom has a BA in Business and Administration from the University of Lund and an MBA from IESE Business School. Mats has also done professional board work with the Michael Berglund Board.